Up-and-coming Tapimmune seeks 'more eyes' on I-O assets with uplisting
By Marie Powers
Friday, August 12, 2016
Immunotherapy developer Tapimmune Inc., which began life back in 2000 as Genemax Corp., quietly inked a series of deals and kept its head down during the formative years of the I-O field.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.